Research programme: antioxidants - Resdevco
Latest Information Update: 16 Jul 2016
At a glance
- Originator Resdevco
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Retinal disorders; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Israel
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in Israel
- 23 May 2006 Preclinical trials in Undefined in Israel (unspecified route)